Metraipolis › archive › dc_ebaf4440a181

1Z2MAP1O — Wikipedia (en)

Source
Wikipedia (en)
Original
https://en.wikipedia.org/wiki/1Z2MAP1O
License (as archived)
CC-BY-SA-4.0
Archived
2026-11-01T08:16:09.733Z
SHA-256 of the archived text
d83566f8452c12178beab747029e1700443fc520482847ab773634c62146b97b
Stable URL of this page
https://metraipolis.com/documento/dc_ebaf4440a181

How to cite

1Z2MAP1O — Wikipedia (en) — Wikipedia (en), https://en.wikipedia.org/wiki/1Z2MAP1O (CC-BY-SA-4.0); archived copy: https://metraipolis.com/documento/dc_ebaf4440a181 (Metraipolis archive dc_ebaf4440a181, sha256 d83566f8452c12178beab747029e1700443fc520482847ab773634c62146b97b)
BibTeX
@misc{dcebaf4440a181,
  title = {1Z2MAP1O — Wikipedia (en)},
  howpublished = {Wikipedia (en)},
  url = {https://en.wikipedia.org/wiki/1Z2MAP1O},
  note = {License CC-BY-SA-4.0; archived copy https://metraipolis.com/documento/dc_ebaf4440a181; sha256 d83566f8452c12178beab747029e1700443fc520482847ab773634c62146b97b},
  year = {2026}
}

Archived text

Reproduced under CC-BY-SA-4.0. Attribution: Wikipedia (en), https://en.wikipedia.org/wiki/1Z2MAP1O. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

1Z2MAP1O, also known as 1-(indolizin-3-yl)-2-(methylamino)propan-1-one, is a monoamine releasing agent and serotonin receptor modulator of the indolizinylethylamine family. It is an analogue of BK-NM-AMT (β-keto-N-methyl-α-methyltryptamine) in which the indole ring has been replaced with an indolizine ring. 1Z2MAP1O has been found to be a serotonin and dopamine releasing agent as well as a weak serotonin 5-HT1B receptor agonist and serotonin 5-HT2B receptor antagonist. Conversely, its activity as a norepinephrine releasing agent was not reported, and it was inactive at the remaining sites of the 47 screened targets. The drug's EC50Tooltip half-maximal effective concentration values for induction of monoamine release were 109 nM for serotonin and 227 nM for dopamine in Chinese hamster ovary (CHO) cells expressing the human monoamine transporters (MATs). The dopamine/serotonin ratio was 0.48. Its EC50 at the serotonin 5-HT1B receptor was 1,130 nM, whereas its IC50Tooltip half-maximal inhibitory concentration values were 2,140 nM at the serotonin 5-HT2B receptor, 2,410 nM at the dopamine transporter (DAT), and 5,690 nM at the norepinephrine transporter (NET). 1Z2MAP1O's inhibition of the serotonin transporter (SERT) was not reported. 1Z2MAP1O was patented by Matthew Baggott of Tactogen in 2023.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (deposito sistematico; retro-catalogo: tutte le voci di Wikipedia in inglese, in ordine alfabetico).
Fonte: Wikipedia in inglese, voce «1Z2MAP1O» — https://en.wikipedia.org/wiki/1Z2MAP1O
Wikidata Q132296132: «pharmaceutical compound» (dati Wikidata in CC0 1.0) — https://www.wikidata.org/wiki/Q132296132
Autori: i contributori di Wikipedia (cronologia: https://en.wikipedia.org/wiki/1Z2MAP1O?action=history).
Licenza: Creative Commons Attribuzione-Condividi allo stesso modo 4.0 (CC BY-SA 4.0) — https://creativecommons.org/licenses/by-sa/4.0/. Il riuso richiede attribuzione e stessa licenza.
Estratto dell'introduzione non modificato nel contenuto; revisione 1332268318, consultata il 2026-11-01T08:06:54.610Z tramite l'API ufficiale di Wikipedia. Impronta SHA-256 dell'estratto: 63228347470a836adf368d1da970aa99a26ecf54ca10e1c64a978ffc39b5de71